FDA Approves Jaypirca (Pirtobrutinib) for Previously Untreated CLL — the Non-Covalent BTK Inhibitor Moves Into the Frontline

FDA Approves Jaypirca (Pirtobrutinib) for Previously Untreated CLL — the Non-Covalent BTK Inhibitor Moves Into the Frontline

October 2, 2026. The FDA approved pirtobrutinib (Jaypirca, Eli Lilly) "for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion¹" — expanding the drug from its relapsed/refractory foothold into the treatment-naïve frontline setting, where it will compete with the established covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib).

The approval rests on BRUIN CLL-313 (NCT05023980), a randomized, open-label trial in 282 previously untreated CLL/SLL patients without 17p deletion, randomized 1:1 to pirtobrutinib 200 mg daily versus six cycles of bendamustine plus a rituximab product. The primary endpoint was investigator-independent progression-free survival, and the result was decisive: "With an estimated median follow-up for PFS of 28 months, the median PFS was not estimable (NE)... in the pirtobrutinib arm and 33.5 months (95% CI: 32.7, NE) in the bendamustine and rituximab arm (Hazard ratio 0.20 [95% CI: 0.11, 0.37]; p-value <0.0001)." That is an 80% reduction in the hazard of progression or death. Overall survival was immature — 13 deaths total, 3 (2.1%) on pirtobrutinib vs 10 (7.1%) on control.

Tolerability is the trade-off to watch: the most common non-laboratory adverse reactions were upper respiratory tract infections (27%), rash (22%), and COVID-19 (21%); serious adverse reactions occurred in 28% of patients, and the label carries warnings for infections, hemorrhage, cytopenias, cardiac arrhythmias, secondary primary malignancies, hepatotoxicity, and embryo-fetal toxicity. Unlike the covalent BTK inhibitors, pirtobrutinib's reversible binding was designed to retain activity after covalent-BTK resistance mutations — a property now being tested at the population scale of frontline therapy.